(Q47866316)

6 February 2018

review article

1 reference

title

Are all type I human interferons equivalent? (English)

1 reference

6 February 2018

author name string

Foster GR

series ordinal

1

1 reference

6 February 2018

Finter NB

series ordinal

2

1 reference

6 February 2018

publication date

1 May 1998

1 reference

6 February 2018

Journal of Viral Hepatitis

published in

1 reference

6 February 2018

volume

5

1 reference

6 February 2018

page(s)

143-152

1 reference

6 February 2018

issue

3

1 reference

6 February 2018

Virus interference. I. The interferon

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. I. Rapid evolution of encephalomyocarditis virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

Interferon-Like Virus-Inhibitor Induced in Human Leukocytes by Phytohemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

Differential expression of human interferon genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

A novel class of human type I interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

Functional subdomains of STAT2 required for preassociation with the alpha interferon receptor and for signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

Alpha and beta interferons and their receptor and their friends and relations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

The type I interferon receptor mediates tyrosine phosphorylation of insulin receptor substrate 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

Interferon-alpha engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3'-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

Use of a selectable marker regulated by alpha interferon to obtain mutations in the signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

Anti-HIV-1 activity of recombinant and hybrid species of interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

A species of human alpha interferon that lacks the ability to boost human natural killer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

Antigen presentation by human monocytes: effects of modifying major histocompatibility complex class II antigen expression and interleukin 1 production by using recombinant interferons and corticosteroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

Selective expression of an interleukin-12 receptor component by human T helper 1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

Comparative effects of interferon-consensus 1, interferon-alpha 2a, and interferon-beta 1b on HLA expression and lymphoproliferation: a preclinical model for treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

Interferons in cell growth and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

Antibodies to interferon-alpha in treated cancer patients: incidence and significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-alpha subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

Management of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

Antiproliferative action of interferon-α requires components of T-cell-receptor signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

Mechanism of the Antitumour Effect of Interferon in Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.1998.00103.X

10.1046/J.1365-2893.1998.00103.X

21 January 2018

Identifiers

DOI

1 reference

6 February 2018

PubMed ID

9658366

1 reference

6 February 2018